Cargando…

Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds

SARS-CoV-2 3C-like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pei, Liu, Hongbo, Sun, Qi, Liang, Hao, Li, Chunmei, Deng, Xiaobing, Liu, Ying, Lai, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395831/
https://www.ncbi.nlm.nih.gov/pubmed/32798789
http://dx.doi.org/10.1016/j.ejmech.2020.112702
Descripción
Sumario:SARS-CoV-2 3C-like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC(50)’s of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs.